Real-World Comparison of Cabazitaxel Versus 177Lu-PSMA Radiopharmaceutical Therapy in Metastatic Castration-Resistant Prostate Cancer
Results: Of 373 patients, 14% received cabazitaxel, 65% received 177Lu-PSMA, and 21% received both.
“Rates of a prostate-specific antigen decline of at least 50% were 32% versus 0% for 177Lu-PSMA versus cabazitaxel.
Results: Of 373 patients, 14% received cabazitaxel, 65% received 177Lu-PSMA, and 21% received both.
“Rates of a prostate-specific antigen decline of at least 50% were 32% versus 0% for 177Lu-PSMA versus cabazitaxel.